Relmada Therapeutics' REL-1017 (esmethadone), and Seelos Therapeutics' SLS-002, an intranasal formulation of racemic ketamine.
Meanwhile, Johnson & Jonson's orexin 2 antagonist seltorexant, Intra-Cellular Therapies' serotonin 5-HT2a antagonist Caplyta (lumateperone), and Relmada Therapeutic' NMDA drug dextromethadone (REL ...
After hours: February 14 at 7:40:30 PM EST Loading Chart for RLMD ...
After hours: February 14 at 7:40:30 p.m. EST ...
SciSparc (SPRC)has reached an important settlement agreement regarding a lawsuit it filed in February 2022 with the Economic Division of the ...
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cybin (CYBN – Research Report) and Corbus ...
After hours: February 14 at 7:50:00 PM EST Loading Chart for ALLK ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback